Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nyse  >  Pfizer Inc       

End-of-day quote. End-of-day quote  - 08/17
35.5 USD   +0.51%
10/02 JPMORGAN CHASE : Dow Movers: JPM, PFE
10/02 PFIZER : Announces Final Results of Exchange Offers
10/02 Novartis biosimilar copycat takes aim at Amgen's drug Enbrel
News SummaryMost relevantAll newsSector news 

Pfizer Inc. : Study Shows Positive Results for Pfizer's Lyrica Treatment for Fibromyalgia

11/19/2012 | 08:40am US/Eastern
   By Saabira Chaudhuri 

Pfizer Inc. (>> Pfizer Inc.) said results of a late-stage study of its pregabalin controlled-release formulation as a treatment for fibromyalgia were positive.

The drug company said top-line results of a Phase 3 study evaluating pregabalin controlled-release formulation, also known as Lyrica, in patients with fibromyalgia indicated that it had a statistically significant positive effect compared with a placebo with regards to time to loss of therapeutic response.

Pfizer described fibromyalgia as a common pain condition in the U.S. affecting more than five million Americans and characterized by chronic widespread pain and tenderness lasting for three or more months.

The most recent study is the second of three Phase 3 studies of the pregabalin controlled-release formulation, which Pfizer said will determine the potential use of pregabalin as a once-a-day therapy.

Last week, Pfizer had revealed that a Phase 3 study showed Lyrica as a potential epilepsy treatment didn't meet the primary endpoint for a change in seizure frequency. Monday, the drug company noted that the final study in post-herpetic neuralgia is ongoing.

"Collectively, the results of these controlled-release studies will allow us to better understand the potential of a once-a-day pregabalin treatment regimen," said Steven J. Romano, head of Pfizer's Global Primary Care Business Unit's Medicines Development Group. "Reducing the number of times patients need to take their medicine per day while maintaining the same efficacy and safety profile could potentially provide a greater convenience and the potential to enhance treatment adherence and outcomes."

Shares edged up 12 cents to $23.98 in recent premarket trading. The stock has risen 22% in the past year.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Pfizer Inc.
React to this article
Latest news on PFIZER INC
10/02 JPMORGAN CHASE : Dow Movers: JPM, PFE
10/02 PFIZER : Announces Final Results of Exchange Offers
10/02 Novartis biosimilar copycat takes aim at Amgen's drug Enbrel
10/01 PROVECTUS BIOPHARMACEUTICALS : Announces Initiation of Phase 1b/2 Clinical Trial..
10/01 PFIZER : Invites Public To View And Listen To Webcast Of Pfizer Presentation At ..
10/01 PFIZER : Sayana® Press Becomes First Injectable Contraceptive In The United King..
10/01 PFIZER : XRpro Sciences Completes Name Change to Icagen, Inc. Following Acquisit..
10/01 PFIZER : Announces Positive Top-Line Results from Two Phase 3 Trials of Oral Tof..
10/01 PFIZER : Completes Acquisition Of Nimenrix And Mencevax From GlaxoSmithKline
10/01 PFIZER : Assigned Patent
Duration : Period :
Pfizer Inc Technical Analysis Chart | 4-Traders
Income Statement Evolution
More Financials